Bellerophon Therapeutics Statistics
Share Statistics
Bellerophon Therapeutics has 12.23M
shares outstanding. The number of shares has increased by 0%
in one year.
| Shares Outstanding | 12.23M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 1.71% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 217,078 |
| FTD / Avg. Volume | 1.59K% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -0.43 and the forward
PE ratio is null.
Bellerophon Therapeutics's PEG ratio is
-0.04.
| PE Ratio | -0.43 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | 3.39 |
| P/FCF Ratio | -0.48 |
| PEG Ratio | -0.04 |
Financial Ratio HistoryEnterprise Valuation
Bellerophon Therapeutics has an Enterprise Value (EV) of 1.87M.
| EV / Sales | 0 |
| EV / EBITDA | -0.08 |
| EV / EBIT | -0.11 |
| EV / FCF | -0.11 |
Financial Position
The company has a current ratio of 1.4,
with a Debt / Equity ratio of 0.
| Current Ratio | 1.4 |
| Quick Ratio | 1.4 |
| Debt / Equity | 0 |
| Debt / EBITDA | -0.01 |
| Debt / FCF | -0.01 |
| Interest Coverage | -165.81 |
Financial Efficiency
Return on Equity is -782.6% and Return on Invested Capital is -787.38%.
| Return on Equity | -782.6% |
| Return on Assets | -249.92% |
| Return on Invested Capital | -787.38% |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-1,101,722.22 |
| Employee Count | 18 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -2.42M |
| Effective Tax Rate | 10.86% |
Stock Price Statistics
The stock price has increased by -81.52% in the
last 52 weeks. The beta is 0.7, so Bellerophon Therapeutics's
price volatility has been higher than the market average.
| Beta | 0.7 |
| 52-Week Price Change | -81.52% |
| 50-Day Moving Average | 0.04 |
| 200-Day Moving Average | 0.05 |
| Relative Strength Index (RSI) | 27.71 |
| Average Volume (20 Days) | 13,687 |
Income Statement
| Revenue | n/a |
| Gross Profit | -65K |
| Operating Income | -22.38M |
| Net Income | -19.83M |
| EBITDA | -22.18M |
| EBIT | -22.25M |
| Earnings Per Share (EPS) | -2.08 |
Full Income StatementBalance Sheet
The company has 6.92M in cash and 203K in
debt, giving a net cash position of 6.72M.
| Cash & Cash Equivalents | 6.92M |
| Total Debt | 203K |
| Net Cash | 6.72M |
| Retained Earnings | -252.08M |
| Total Assets | 4.98M |
| Working Capital | 3.72M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -17.77M
and capital expenditures 0, giving a free cash flow of -17.77M.
| Operating Cash Flow | -17.77M |
| Capital Expenditures | n/a |
| Free Cash Flow | -17.77M |
| FCF Per Share | -1.86 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
